1367 related articles for article (PubMed ID: 24120221)
21. Rivaroxaban: a review of its use in the treatment of deep vein thrombosis or pulmonary embolism and the prevention of recurrent venous thromboembolism.
Burness CB; Perry CM
Drugs; 2014 Feb; 74(2):243-62. PubMed ID: 24430916
[TBL] [Abstract][Full Text] [Related]
22. [New oral anticoagulants in the treatment of venous thromboembolic disease].
Calvo Romero JM; Lima Rodríguez EM
Semergen; 2013 Apr; 39(3):146-9. PubMed ID: 23540987
[TBL] [Abstract][Full Text] [Related]
23. Prevention of Venous Thromboembolism after Arthroscopic Knee Surgery in a Low-Risk Population with the Use of Aspirin. A Randomized Trial.
Kaye ID; Patel DN; Strauss EJ; Alaia MJ; Garofolo G; Martinez A; Jazrawi LM
Bull Hosp Jt Dis (2013); 2015 Dec; 73(4):243-8. PubMed ID: 26630467
[TBL] [Abstract][Full Text] [Related]
24. Failure of dabigatran and rivaroxaban to prevent thromboembolism in antiphospholipid syndrome: a case series of three patients.
Schaefer JK; McBane RD; Black DF; Williams LN; Moder KG; Wysokinski WE
Thromb Haemost; 2014 Nov; 112(5):947-50. PubMed ID: 25118790
[TBL] [Abstract][Full Text] [Related]
25. Venous thromboembolism management: where do novel anticoagulants fit?
Spyropoulos AC; Turpie AG
Curr Med Res Opin; 2013 Jul; 29(7):783-90. PubMed ID: 23659584
[TBL] [Abstract][Full Text] [Related]
26. Prophylaxis of venous thromboembolism: low molecular weight heparin compared to the selective anticoagulants rivaroxaban, dabigatran and fondaparinux.
Welzel D; Hull R; Fareed J
Int Angiol; 2011 Jun; 30(3):199-211. PubMed ID: 21617603
[TBL] [Abstract][Full Text] [Related]
27. Indirect comparison and cost-utility of dabigatran etexilate and rivaroxaban in the treatment and extended anticoagulation of venous thromboembolism in a UK setting.
Jugrin AV; Hösel V; Ustyugova A; De Francesco M; Lamotte M; Sunderland T
J Med Econ; 2016; 19(1):1-10. PubMed ID: 26390231
[TBL] [Abstract][Full Text] [Related]
28. Diagnosis and Treatment of Lower Extremity Venous Thromboembolism: A Review.
Chopard R; Albertsen IE; Piazza G
JAMA; 2020 Nov; 324(17):1765-1776. PubMed ID: 33141212
[TBL] [Abstract][Full Text] [Related]
29. Trial Protocol: a randomised controlled trial of extended anticoagulation treatment versus routine anticoagulation treatment for the prevention of recurrent VTE and post thrombotic syndrome in patients being treated for a first episode of unprovoked VTE (The ExACT Study).
Tullett J; Murray E; Nichols L; Holder R; Lester W; Rose P; Hobbs FD; Fitzmaurice D
BMC Cardiovasc Disord; 2013 Mar; 13():16. PubMed ID: 23497371
[TBL] [Abstract][Full Text] [Related]
30. Predictive value of D-dimer test for recurrent venous thromboembolism after anticoagulation withdrawal in subjects with a previous idiopathic event and in carriers of congenital thrombophilia.
Palareti G; Legnani C; Cosmi B; Valdré L; Lunghi B; Bernardi F; Coccheri S
Circulation; 2003 Jul; 108(3):313-8. PubMed ID: 12847064
[TBL] [Abstract][Full Text] [Related]
31. Residual venous obstruction, alone and in combination with D-dimer, as a risk factor for recurrence after anticoagulation withdrawal following a first idiopathic deep vein thrombosis in the prolong study.
Cosmi B; Legnani C; Iorio A; Pengo V; Ghirarduzzi A; Testa S; Poli D; Tripodi A; Palareti G;
Eur J Vasc Endovasc Surg; 2010 Mar; 39(3):356-65. PubMed ID: 20034816
[TBL] [Abstract][Full Text] [Related]
32. An Algorithmic Approach to Management of Venous Thromboembolism.
Dhakal P; Gundabolu K; Bhatt VR
Clin Appl Thromb Hemost; 2017 Sep; 23(6):511-517. PubMed ID: 27268941
[TBL] [Abstract][Full Text] [Related]
33. Rivaroxaban for the prevention of venous thromboembolism: a single technology appraisal.
Stevenson M; Scope A; Holmes M; Rees A; Kaltenthaler E
Health Technol Assess; 2009 Oct; 13 Suppl 3():43-8. PubMed ID: 19846028
[TBL] [Abstract][Full Text] [Related]
34. [Questions--answers on the use of rivaroxaban for the treatment of venous thromboembolic disease].
Pernod G; Elias A; Gouin I; Gaillard C; Nguyen P; Ouvry P; Sié P
J Mal Vasc; 2012 Dec; 37(6):300-10. PubMed ID: 23122646
[TBL] [Abstract][Full Text] [Related]
35. The optimal duration of anticoagulation in patients with venous thromboembolism: how long is long enough?
Prandoni P; Piovella C; Spiezia L; Dalla Valle F; Pesavento R
Panminerva Med; 2012 Mar; 54(1):39-44. PubMed ID: 22278115
[TBL] [Abstract][Full Text] [Related]
36. Management of venous thromboembolism.
Burnett B
Prim Care; 2013 Mar; 40(1):73-90. PubMed ID: 23402462
[TBL] [Abstract][Full Text] [Related]
37. Prognostic significance of residual venous obstruction in patients with treated unprovoked deep vein thrombosis: a patient-level meta-analysis.
Donadini MP; Ageno W; Antonucci E; Cosmi B; Kovacs MJ; Le Gal G; Ockelford P; Poli D; Prandoni P; Rodger M; Saccullo G; Siragusa S; Young L; Bonzini M; Caprioli M; Dentali F; Iorio A; Douketis JD
Thromb Haemost; 2014 Jan; 111(1):172-9. PubMed ID: 24154729
[TBL] [Abstract][Full Text] [Related]
38. Oral rivaroxaban for symptomatic venous thromboembolism.
; Bauersachs R; Berkowitz SD; Brenner B; Buller HR; Decousus H; Gallus AS; Lensing AW; Misselwitz F; Prins MH; Raskob GE; Segers A; Verhamme P; Wells P; Agnelli G; Bounameaux H; Cohen A; Davidson BL; Piovella F; Schellong S
N Engl J Med; 2010 Dec; 363(26):2499-510. PubMed ID: 21128814
[TBL] [Abstract][Full Text] [Related]
39. Treatment of DVT: how long is enough and how do you predict recurrence.
Agnelli G; Becattini C
J Thromb Thrombolysis; 2008 Feb; 25(1):37-44. PubMed ID: 17906973
[TBL] [Abstract][Full Text] [Related]
40. Case-fatality of recurrent venous thromboembolism and major bleeding associated with aspirin, warfarin, and direct oral anticoagulants for secondary prevention.
Wu C; Alotaibi GS; Alsaleh K; Linkins LA; McMurtry MS
Thromb Res; 2015 Feb; 135(2):243-8. PubMed ID: 25488466
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
